Welcome to our dedicated page for CG Oncology SEC filings (Ticker: CGON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CG Oncology, Inc. filings document the public-company record of a late-stage clinical biopharmaceutical issuer focused on cretostimogene grenadenorepvec for non-muscle invasive bladder cancer. Recent Form 8-K reports disclose financial results, Regulation FD materials, clinical-program updates, FDA-related communications, executive appointments, board changes and other material events.
The company's SEC record also includes proxy disclosures on board structure, compensation and stockholder matters, along with registration and prospectus materials related to common-stock offerings under an open market sale agreement. These filings describe CG Oncology's Nasdaq-listed common stock, capital-raising activity, governance framework, clinical development priorities and risk-related disclosure context.
CG Oncology, Inc. (CGON) has a notice under Rule 144 from officer Ambaw Bellete covering the proposed sale of 29,630 shares of common stock, expected to be sold on September 2, 2026 following a stock option exercise, through Morgan Stanley Smith Barney LLC.
The notice lists an aggregate market value for these planned sales of $2,299,448.00, and states that CG Oncology had 88,640,375 shares of common stock outstanding. It also details multiple prior open-market sales by Ambaw Bellete over the past three months, including several blocks of 50,000–100,000 shares.
CG Oncology, Inc. (CGON) received a notice under Rule 144 from officer Ambaw Bellete covering a proposed sale of 50,000 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $3,775,250.00 and 88,640,375 shares outstanding as of 08/31/2026.
The shares are to be sold on or after 08/31/2026 in connection with a stock option exercise for cash. The notice also lists multiple prior sales of CG Oncology common stock by Ambaw Bellete during the past three months, including several transactions of tens of thousands of shares.
CG Oncology, Inc. (CGON) has a notice of proposed resale of its common stock under Rule 144 filed on behalf of Ambaw Bellete. The filing lists an arrangement through Morgan Stanley Smith Barney LLC – Executive Financial Services for the potential sale of 5,789 shares of common stock, with a closing date referenced as August 27, 2026.
The notice also lists multiple prior sales of CG Oncology common stock by Ambaw Bellete over the past three months, each with specific share amounts and total dollar values, indicating ongoing secondary market selling activity by this holder. These transactions relate to existing shares and a stock option exercise, rather than a new issuance by CG Oncology.
CG Oncology, Inc. (CGON) received a notice under Rule 144 from officer Ambaw Bellete covering proposed sales of common stock. The notice lists a planned sale of 10,551 shares of common stock to be sold for cash on or about August 25, 2026, following a stock option exercise. It also details multiple prior sales of CGON common shares by Bellete over the past three months, including several large transactions in July and August 2026.
CG Oncology, Inc. (CGON) received a Form 144 notice from officer Ambaw Bellete for a proposed sale of 5,762 shares of common stock. The shares are to be sold following a stock option exercise, with Morgan Stanley Smith Barney LLC listed as the broker. The notice also reports multiple prior sales of CG Oncology common stock by Bellete over the past three months, including several large blocks in July and August 2026.
CG Oncology, Inc. (CGON) reports that officer Ambaw Bellete has filed a notice under Rule 144 to allow the sale of up to 100,000 shares of the company’s common stock through Morgan Stanley Smith Barney LLC, with an indicated value of $7,954,105.00 as of 08/19/2026.
The notice also lists planned cash exercises of stock options for 50,000 shares on 08/03/2026 and 50,000 shares on 08/19/2026. In the prior three months, Bellete has reported multiple open-market sales of common stock, including 75,000 shares on 08/06/2026 for $5,672,212.50 and 50,000 shares on 08/11/2026 for $3,810,255.00.
CG Oncology, Inc. (CGON) director Leonard E. Post reported an option exercise and related share sale. On 2026-08-14 he exercised a fully vested director stock option for 1,000 shares of common stock at an exercise price of $0.60 per share, then sold 1,000 shares of common stock at $74.54 per share in a transaction reported as a sale in the open market or a private transaction. After the exercise, he held 104,077 director stock options directly. The sale was carried out under a Rule 10b5-1 trading plan adopted on March 5, 2026.
CGON insider Ambaw Bellete filed a notice to sell common stock under Rule 144. The planned transaction lists 52,438 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on 08/17/2026, in connection with a stock option exercise.
The filing also lists multiple prior open-market sales of CGON common stock by Ambaw Bellete during the past three months, including individual sales such as 75,000 shares on 08/06/2026 and several sales of 50,000 shares on various dates, each with stated dollar amounts.
CGON shareholder Ambaw Bellete has notified intent to sell 19,364 shares of common stock through Morgan Stanley Smith Barney LLC on 08/14/2026, following a stock option exercise paid in cash. The notice also lists multiple prior open-market sales of CGON common stock over the past three months with individual transactions as large as 75,000 shares.
CG Oncology, Inc. has updated institutional ownership disclosures, showing several Foresite Capital funds and James B. Tananbaum as beneficial owners of its common stock. Based on 88,640,375 shares outstanding as of August 4, 2026, the reported positions each represent under 5% of the company.
Foresite Capital Fund V, L.P. and its manager report 1,079,050 shares (1.2%), Foresite Capital Opportunity Fund V, L.P. 857,550 shares (1.0%), and Foresite Capital Fund VI 2,369,574 shares (2.7%). James B. Tananbaum may be deemed to beneficially own 4,306,174 shares, or 4.9%.